

### Remarks

This will confirm a telephone discussion held today between Examiner Robinson and Applicants' attorney, during which Applicants' attorney informed the Examiner that errors had occurred in amended claim 1 set forth in the Amendment filed June 16, 2005. The purpose of the instant Supplemental Amendment is to correct those errors.

Thus, when claim 1 was previously amended, the revised definition for  $R_2$  incorporated subject matter from claim 9, but claim 9 was directed to a definition for  $R_3$ , rather than  $R_2$ .

Accordingly, claim 1 has now been further amended, as set forth above, to redefine the substituents for the  $R_2$  benzyl and alkyl groups, on the basis of the disclosure at page 4, lines 29-35 of the specification.

In addition, claim 1 has been amended to redefine the substituents for the  $R_3$  cycloalkyl and cycloalkenyl groups in the same manner as in claim 9, which was cancelled from the application by the Amendment filed June 16, 2005. The definition for the substituents for the aryl and heterocyclic groups remains the same as in previously amended claim 1, i.e. incorporating the definitions for these substituents from claim 11, previously cancelled by the Amendment of June 16, 2005.


Furthermore, claim 6 has two different definitions for  $R_2$ . To correct this, the second occurrence of " $R_2$  is" in claim 6 has been deleted.

Further examination, based on the claims as now set forth above, is requested.

Respectfully submitted,

Keiichi IMAMURA et al.

By:



Michael R. Davis

Registration No. 25,134

Attorney for Applicants

MRD/pth  
Washington, D.C. 20006-1021  
Telephone (202) 721-8200  
Facsimile (202) 721-8250  
February 10, 2006